215 related articles for article (PubMed ID: 19524477)
1. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
van Laar T; Postma AG; Drent M
Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
[No Abstract] [Full Text] [Related]
2. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
[TBL] [Abstract][Full Text] [Related]
3. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
4. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
6. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Albani C; Zangger I; Fischer G
Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Zoldan J; Friedberg G; Weizman A; Melamed E
Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
[No Abstract] [Full Text] [Related]
9. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
Matsui H; Udaka F; Tamura A; Oda M; Kubori T; Nishinaka K; Kameyama M
J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):36-40. PubMed ID: 16449759
[TBL] [Abstract][Full Text] [Related]
10. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
Borgemeester RW; Drent M; van Laar T
Parkinsonism Relat Disord; 2016 Feb; 23():17-22. PubMed ID: 26709292
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
[No Abstract] [Full Text] [Related]
13. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
14. Use of apomorphine in clinical practice.
MacMahon DG
Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
[No Abstract] [Full Text] [Related]
15. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
16. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
Alegret M; Valldeoriola F; Martí M; Pilleri M; Junqué C; Rumià J; Tolosa E
Mov Disord; 2004 Dec; 19(12):1463-9. PubMed ID: 15390065
[TBL] [Abstract][Full Text] [Related]
17. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
[TBL] [Abstract][Full Text] [Related]
18. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
[TBL] [Abstract][Full Text] [Related]
19. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
20. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
